NASDAQ · GRAL
Healthcare · Medical - Diagnostics & Research
$128.99
Down-$3.91 (-2.94%)
Updated Oct 8, 2026, 1:50 PM
SID Score
6.5/10
Composite research score
Smart Money
62/100
Neutral
Price performance · GRAL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
GRAL closed at $132.74 after 21 trading sessions, up 71.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $133.46 | $133.46 | $131.00 | $132.744 | 1.72K |
| Oct 7, 2026 | $134.00 | $139.00 | $130.56 | $132.90 | 993.22K |
| Oct 6, 2026 | $159.43 | $166.475 | $135.80 | $137.28 | 2.04M |
| Oct 5, 2026 | $143.00 | $156.49 | $140.305 | $154.08 | 1.47M |
| Oct 2, 2026 | $135.52 | $143.50 | $134.45 | $143.26 | 875.34K |
| Oct 1, 2026 | $138.23 | $141.54 | $132.04 | $132.56 | 1.09M |
| Sep 30, 2026 | $138.27 | $151.4574 | $136.00 | $140.12 | 1.92M |
| Sep 29, 2026 | $132.75 | $140.88 | $131.20 | $136.57 | 922.97K |
| Sep 28, 2026 | $128.90 | $134.4199 | $126.74 | $132.63 | 1.11M |
| Sep 25, 2026 | $123.50 | $127.67 | $118.45 | $126.89 | 1.29M |
| Sep 24, 2026 | $105.50 | $126.81 | $101.98 | $125.21 | 3.45M |
| Sep 22, 2026 | $106.75 | $112.58 | $104.00 | $108.52 | 3.26M |
| Sep 21, 2026 | $93.74 | $111.50 | $92.00 | $107.97 | 3.53M |
| Sep 18, 2026 | $81.48 | $82.85 | $78.20 | $80.77 | 3M |
| Sep 17, 2026 | $75.29 | $81.76 | $75.29 | $79.95 | 1.53M |
| Sep 16, 2026 | $75.95 | $78.86 | $74.12 | $75.11 | 1.62M |
| Sep 15, 2026 | $75.44 | $77.93 | $74.27 | $75.89 | 1.51M |
| Sep 14, 2026 | $74.68 | $76.56 | $73.46 | $75.53 | 1.15M |
| Sep 11, 2026 | $77.61 | $79.19 | $76.14 | $76.23 | 360.99K |
| Sep 10, 2026 | $75.93 | $79.00 | $75.09 | $77.56 | 897.06K |
| Sep 9, 2026 | $78.96 | $81.175 | $76.99 | $77.48 | 591.09K |
The latest Smart Investors Daily articles mentioning GRAL.
Company
Market Activity
Research & News
GRAL research
Company profile and research snapshot.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | UBS | Buy | — |
| Oct 1, 2026 | Guggenheim | Buy | — |
| Sep 28, 2026 | Canaccord Genuity | Buy | — |
| Sep 25, 2026 | Mizuho | Neutral | — |
| Sep 22, 2026 | Baird | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 4, 2026
Mentioning how the FDA advisory panel backed its Galleri multi-cancer early detection test, a caller asked for Jim Cramer’s opinion on GRAIL, Inc. (NASDAQ:GRAL) during the lightning round of the September 30 episode of Mad Money. He replied: You know, I’ve been waiting for that. I’ve been waiting for that approval. And I said, “If […]
Yahoo · Oct 4, 2026
Grail received some excellent news from the FDA this week, but there's still a long way to go before the company meets analyst projections.
Yahoo · Oct 3, 2026
In September 2026, GRAIL announced that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the...
Benzinga · Oct 2, 2026
UBS analyst Doug Schenkel maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $105 to $175.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GRAL.
